Bronchoconstriction by nebulized metabisulfite solutions (SO2) and its modification by ipratropium bromide.
Seale Jp, Temple Dm, Tennant Cm
Abstract
Seale Jp, Temple Dm, Tennant Cm
Abstract
A nebulized solution of sodium metabisulfite (MBS) induced bronchoconstriction in nine subjects with asthma. An anticholinergic drug, ipratropium bromide (IPRA), in doses (500 to 700 micrograms) which were found to inhibit methacholine-induced bronchoconstriction, protected three of the nine subjects against nebulized MBS. These results suggest that both cholinergic and non-cholinergic reflex mechanisms are involved in MBS-induced bronchoconstriction.
OpenAlex reports 10 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
A nebulized solution of sodium metabisulfite (MBS) induced bronchoconstriction in nine subjects with asthma. An anticholinergic drug, ipratropium bromide (IPRA), in doses (500 to 700 micrograms) which were found to inhibit methacholine-induced bronchoconstriction, protected three of the nine subjects against nebulized MBS. These results suggest that both cholinergic and non-cholinergic reflex mechanisms are involved in MBS-induced bronchoconstriction.
Key concepts: Bronchoconstriction, Ipratropium bromide, Medicine, Methacholine, Anesthesia, Ipratropium, Cholinergic, Sodium metabisulfite